Baseline Characteristics
| N= 795 | |
|---|---|
| Age, mean SD | 52.44 (±12.99) |
| Sex, n (%) | |
| Female | 734 |
| Male | 61 |
| Methotrexate (mg/week) | |
| Average Dose | 19.94 |
| Median Dose | 20 |
| Intramuscular | 79 (9.93%) |
| Subcutaneous | 113 (14.21%) |
| Oral | 603 (75.84%) |
| Disease Activity according to DAS28 ESR, n (%) | |
| Remission | 343 (42.3) |
| Low activity | 101 (12.5) |
| Moderate activity | 292 (36.0) |
| High activity | 59 (7.3) |
| Adherence classification according to prescribed doses taken, n (%) | |
| Absent (<25%) | 20 (2.5%) |
| Poor (25-49%) | 19 (2.3%) |
| Regular (50-74%) | 55 (6.8%) |
| Adequate (>75%) | 701 (86.5%) |